Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970680 | 0.82 | SLC6A2 (0.40) | SMN1; SMN2SLC6A2TP53NPC1RAB9A | |
| SCHEMBL6472453 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2BACE1NPC1RAB9AKDM4E | |
| SCHEMBL18317487 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2BACE1NPC1KDM4EKMT2A | |
| SCHEMBL5201509 | 0.76 | TP53 (0.47) | SMN1; SMN2TP53NPC1RAB9AKDM4E | |
| SCHEMBL11747741 | 0.75 | KMT2A (0.59) | SMN1; SMN2BACE1NPC1RAB9AKDM4E | |
| SCHEMBL5642556 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2BACE1NPC1RAB9AKDM4E | |
| SCHEMBL3969742 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2BACE1NPC1RAB9AKDM4E | |
| SCHEMBL2592356 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2BACE1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL10901769 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL22408296 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2BACE1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| EP-2606032-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | University Of Washington Through Its Center For Commercialization (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2003040103-A1 | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | SMN1; SMN2 3011/4885SLC6A2 2111/4885BACE1 72/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SMN1; SMN2 2335/4885SLC6A2 326/4885BACE1 1263/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SMN1; SMN2 2335/4885SLC6A2 326/4885BACE1 1263/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SMN1; SMN2 2335/4885SLC6A2 326/4885BACE1 1263/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SMN1; SMN2 2335/4885SLC6A2 326/4885BACE1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.